• SPX
  • $5,758.27
  • 0.8 %
  • $45.58
  • DJI
  • $42,157.24
  • 0.87 %
  • $362.64
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,158.64
  • -0.31 %
  • -$25.60
  • IXIC
  • $18,363.27
  • 1.01 %
  • $183.29
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News & Analysis

Sarepta Therapeutics, Inc. (SRPT) Stock Price, News & Analysis

Currency in USD Disclaimer

$121.85

-$1.22

(-0.99%)

Day's range
$121.18
Day's range
$123.55
50-day range
$116.17
Day's range
$140.97
  • Country: US
  • ISIN: US8036071004
52 wk range
$75.85
Day's range
$173.25
  • CEO: Mr. Douglas S. Ingram Esq.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 2.32
  • Piotroski Score 4.00
  • Grade Outperform
  • Symbol (SRPT)
  • Company Sarepta Therapeutics, Inc.
  • Price $121.85
  • Changes Percentage (-0.99%)
  • Change -$1.22
  • Day Low $121.18
  • Day High $123.55
  • Year High $173.25

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/06/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $172.00
  • High Stock Price Target $203.00
  • Low Stock Price Target $94.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $0.43
  • Trailing P/E Ratio 286.79
  • Forward P/E Ratio 286.79
  • P/E Growth 286.79
  • Net Income $-535,977,000

Income Statement

Quarterly

Annual

Latest News of SRPT

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.